Hartman Corina, Berkowitz Drora, Weiss Batia, Shaoul Ron, Levine Arie, Adiv Orly Eshach, Shapira Riki, Fradkin Akiva, Wilschanski Michael, Tamir Ada, Shamir Raanan
Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Isr Med Assoc J. 2008 Jul;10(7):503-7.
A polymeric diet rich in transforming growth factor-beta 2 used as a single nutrient has been shown to induce remission in 79% of children with Crohn's disease.
To summarize the experience of several pediatric gastroenterology units in Israel using a TGFbeta2-enriched polymeric diet (Modulen IBD) supplementation in children and adolescents with Crohn's disease.
In a retrospective study we reviewed the charts of 28 children with Crohn's disease (10 girls, 18 boys) who received, in addition to conventional treatment, Modulen IBD as a supplement to their regular nutrition. These children were compared with 18 children supplemented with standard polymeric formula (Ensure Plus) and 18 children without formula supplementation. We recorded clinical manifestations, growth, and the Pediatric Crohn's Disease Activity Index before and after initiation of the polymeric diet.
The Modulen-treated children showed a significant decrease in PCDAI from 34.3 to 15.7 (P< 0.0001). A significant decrease in PCDAI was recorded also in the Ensure Plus group, from 35 to 22 (P= 0.02) but not in the non-supplemented group. Significant improvements in body mass index (P = 0.01) and erythrocyte sedimentation rate (P= 0.03) were recorded at follow-up (median 3.4 months) only in the Modulen IBD group.
In this cohort of children with Crohn's disease, supplementation of the diet with Modulen IBD as well as supplementation with Ensure Plus was associated with a decrease in PCDAI. The children supplemented with Modulen IBD also showed improvement in BMI, suggesting an additional advantage of nutritional therapy in children with this disease.
富含转化生长因子-β2的聚合饮食作为单一营养素已被证明可使79%的克罗恩病儿童病情缓解。
总结以色列多个儿科胃肠病科使用富含转化生长因子-β2的聚合饮食（Modulen IBD）补充剂治疗儿童和青少年克罗恩病的经验。
在一项回顾性研究中，我们查阅了28例克罗恩病患儿（10例女孩，18例男孩）的病历，这些患儿除接受常规治疗外，还使用Modulen IBD作为常规营养补充剂。将这些患儿与18例补充标准聚合配方奶粉（安素）的患儿以及18例未补充配方奶粉的患儿进行比较。我们记录了开始聚合饮食前后的临床表现、生长情况以及儿童克罗恩病活动指数。
接受Modulen治疗的患儿的儿童克罗恩病活动指数从34.3显著降至15.7（P<0.0001）。安素组的儿童克罗恩病活动指数也显著下降，从35降至22（P=0.02），但未补充组则未出现显著下降。仅在Modulen IBD组的随访中（中位时间3.4个月），体重指数（P = 0.01）和红细胞沉降率（P=0.03）有显著改善。
在这组克罗恩病患儿中，补充Modulen IBD饮食以及补充安素均与儿童克罗恩病活动指数下降有关。补充Modulen IBD的患儿的体重指数也有所改善，表明营养治疗对该病患儿还有额外益处。
